PLBD1

Across TCGA pan-cancer cohorts, PLBD1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLBD1 data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PLBD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLBD1 expression acts as an unfavorable survival marker.

KIRC, SARC, and UCEC are the cancer types where PLBD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.249	0.805	.010	12	view →
SARC	OS	Median	All	0.178	0.745	.008	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	All	0.240	0.713	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLBD1–KIRC (OS)

Open the KIRC breakdown →